BioLargo reports preliminary Q2 revenue $5M, up 247% vs. last year

Companywide revenue for the quarter increased 247% compared with the second quarter of 2023 and increased 5% compared to the first quarter of 2024. The company had a net loss for the quarter of $780,000, which included approximately $540,000 in non-cash stock option compensation expense. At June 30, 2024, the company had $4.8 million in cash and cash equivalents, and $10.1 million total assets. The company’s total stockholder’s equity increased to $5.9 million as of June 30, 2024. BioLargo’s President and CEO Dennis P. Calvert said of the results, “We had another quarter of record revenues, and we continue to strengthen our balance sheet. We are in a strong position to continue advancing the commercialization of our multiple cleantech products and services.”